12. Attenuated Bacterial Vaccines
- W. John W. Morrow PhD, DSc, FRCPath3,
- Nadeem A. Sheikh PhD4,
- Clint S. Schmidt PhD5,
- D. Huw Davies PhD6
Published Online: 20 JUN 2012
DOI: 10.1002/9781118345313.ch12
Copyright © 2012 Blackwell Publishing Ltd
Book Title
Vaccinology: Principles and Practice
Additional Information
How to Cite
Titball, R. W. and Atkins, H. S. (2012) Attenuated Bacterial Vaccines, in Vaccinology: Principles and Practice (eds W. J. W. Morrow, N. A. Sheikh, C. S. Schmidt and D. H. Davies), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781118345313.ch12
Editor Information
- 3
Seattle, WA, USA
- 4
Dendreon Corporation, Seattle, WA, USA
- 5
NovaDigm Therapeutics, Inc., Grand Forks, ND, USA
- 6
University of California at Irvine, Irvine, CA, USA
Publication History
- Published Online: 20 JUN 2012
- Published Print: 3 AUG 2012
ISBN Information
Print ISBN: 9781405185745
Online ISBN: 9781118345313
- Summary
- Chapter
- References
Keywords:
- vaccine;
- live vaccine;
- attenuated mutant;
- rationally attenuated;
- auxotroph;
- vaccine vector
Summary
A number of live attenuated bacterial vaccines have been generated using empirical methods and have been widely used. However, these vaccines are considered generally poorly effective. In addition, the genetic basis of attenuation is often unknown and these vaccines may be unsafe for use in immunocompromised hosts. Thus, there is a requirement for rationally attenuated bacterial mutants that may be used as safe and efficacious live vaccines for a range of diseases. This chapter reviews data on the efficacy of live attenuated bacterial vaccines, and considers the reasons why the performance of these vaccines requires improvement. The potential for the next generation of live attenuated vaccines to resolve these limitations will be reviewed. Finally, the prospects, limitations, and pitfalls for the exploitation of rationally attenuated live vaccines as carriers of heterologous antigens are considered.